ONCT Oncternal Therapeutics Inc.

5.91
+0.07  (+1%)
Previous Close 5.84
Open 5.98
Price To Book 5.01
Market Cap 90,938,600
Shares 15,387,242
Volume 17,302
Short Ratio
Av. Daily Volume 24,147
Stock charts supplied by TradingView

NewsSee all news

  1. Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief

  2. Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting

    Interim data from Phase 1 study in patients with Ewing sarcoma show TK216 has been generally well tolerated One of two patients at the current, highest TK216 exposure dose regimen has experienced a deep and sustained

  3. Oncternal Therapeutics to Present at Stifel Healthcare Conference

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief

  4. Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update

    Opened randomized, Phase 2 clinical trial of cirmtuzumab in combination with ibrutinib in patients with CLL and Phase 1b expansion cohort in patients with MCL, based on encouraging interim clinical results Reported

  5. Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 – an investigational targeted

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data to be presented at CTOS November 2019.
TK216 and vincristine
Relapsed or refractory Ewing sarcoma
Phase 1 data due 4Q 2019.
Cirmtuzumab and paclitaxel
Breast cancer
Phase 2 data due at ASH December 7, 2019, 5:30 PM ET.
Cirmtuzumab and ibrutinib
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)

Latest News

  1. Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief

  2. Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting

    Interim data from Phase 1 study in patients with Ewing sarcoma show TK216 has been generally well tolerated One of two patients at the current, highest TK216 exposure dose regimen has experienced a deep and sustained

  3. Oncternal Therapeutics to Present at Stifel Healthcare Conference

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief

  4. Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update

    Opened randomized, Phase 2 clinical trial of cirmtuzumab in combination with ibrutinib in patients with CLL and Phase 1b expansion cohort in patients with MCL, based on encouraging interim clinical results Reported

  5. Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 – an investigational targeted

  6. Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2019 financial results

  7. Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma

    Cirmtuzumab combination demonstrated clinical activity with complete responses in mantle cell lymphoma Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development

  8. Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Children's Oncology Group Meeting

    Sustained objective response reported for patient with challenging pediatric cancer Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology

  9. Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of